Identification

Name
Ranitidine
Accession Number
DB00863  (APRD00254)
Type
Small Molecule
Groups
Approved
Description

A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers. [PubChem]

Structure
Thumb
Synonyms
  • RAN
  • Ranitidina
  • Ranitidinum
Product Ingredients
IngredientUNIICASInChI Key
Ranitidine bismuth citrate7AJ51I17KG128345-62-0XAUTYMZTJWXZHZ-UHFFFAOYSA-K
Ranitidine HydrochlorideBK76465IHM66357-59-3GGWBHVILAJZWKJ-KJEVSKRMSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Acid ReducerTablet150 mgOralPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
Act RanitidineTablet300 mgOralTeva2004-02-19Not applicableCanada
Act RanitidineTablet150 mgOralTeva2004-04-19Not applicableCanada
Bci RanitidineTablet300 mgOralBaker Cummins IncNot applicableNot applicableCanada
Bci RanitidineTablet150 mgOralBaker Cummins IncNot applicableNot applicableCanada
M-ranitidineTablet300 mgOralMantra Pharma IncNot applicableNot applicableCanada
M-ranitidineTablet150 mgOralMantra Pharma IncNot applicableNot applicableCanada
Med Ranitidine Tablets 150mgTablet150 mgOralMedican Pharma Incorporated1999-04-062011-03-29Canada
PyloridTablet400 mgOralGlaxo Wellcome1997-08-292000-07-27Canada
RanitidineTablet300 mgOralMylan Pharmaceuticals2009-10-222012-10-19Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-ranitidineSolution75 mgOralApotex Corporation2006-07-14Not applicableCanada
Apo-ranitidine Tablet 150mgTablet150 mgOralApotex Corporation1987-12-31Not applicableCanada
Apo-ranitidine Tablet 300mgTablet300 mgOralApotex Corporation1987-12-31Not applicableCanada
Dom-ranitidineTablet150 mgOralDominion Pharmacal2001-03-22Not applicableCanada
Dom-ranitidineTablet300 mgOralDominion Pharmacal2001-03-22Not applicableCanada
Good Sense Acid ReducerTablet75 mg/1Oralbryant ranch prepack2009-05-21Not applicableUs
Inflammation Reduction PackKitTmig, Inc.2015-08-18Not applicableUs
Jamp-ranitidineTablet300 mgOralJamp Pharma CorporationNot applicableNot applicableCanada
Jamp-ranitidineTablet150 mgOralJamp Pharma CorporationNot applicableNot applicableCanada
Mar-ranitidineTablet300 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
7 Select Acid ReducerTablet, film coated150 mg/1Oral7 Eleven2014-04-22Not applicableUs
Acid ReducerTablet150 mg/1OralFred's2012-03-30Not applicableUs
Acid ReducerTablet, film coated150 mg/1OralNash Finch2013-06-152018-07-15Us
Acid ReducerTablet, film coated150 mg/1OralH.E.B.2015-11-30Not applicableUs
Acid ReducerTablet, film coated75 mg/1OralGood Sense2013-10-11Not applicableUs
Acid ReducerTablet75 mgOralMylan Pharmaceuticals1998-06-252016-11-02Canada
Acid ReducerTablet, film coated150 mg/1OralShopko Stores Operating2013-06-05Not applicableUs
Acid ReducerTablet, film coated150 mg/1OralRite Aid2011-10-26Not applicableUs
Acid ReducerTablet75 mgOralApotex Corporation1999-02-08Not applicableCanada
Acid ReducerTablet, coated75 mg/1OralH.E.B.2016-10-27Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
DeramsilkRx Anodynexa PakRanitidine Hydrochloride (150 mg/1) + Capsicum oleoresin (0.25 mg/1mL) + Diclofenac sodium (75 mg/1)KitPatchwerx Labs2015-06-12Not applicableUs
DermacinRx Inflammatral PakRanitidine Hydrochloride (150 mg/1) + Capsicum oleoresin (0.25 mg/1mL) + Diclofenac sodium (75 mg/1)KitPure Tek Corporation2015-06-12Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
DeprizineRanitidine HydrochlorideKitCalifornia Pharmaceuticals, Llc2016-01-012018-01-10Us
GabitidineRanitidine Hydrochloride + CholineKitPhysician Therapeutics Llc2011-07-072016-10-13Us
Ranitidine Hydrochloride Oral Suspension KitRanitidine HydrochlorideKitCalifornia Pharmaceuticals, Llc2017-01-02Not applicableUs
SentradineRanitidine Hydrochloride + CholineKitPhysician Therapeutics Llc2011-07-072016-10-13Us
International/Other Brands
Alquen / Coralen / Gastrolav / Gastrosedol / Kuracid / Nu-Ranit / Pep-Rani / Ptinolin / Raniberl / Ranibloc / Ranicux / Ranidil / Ranidin / Ranidine / Ranidura / Ranifur / Ranigast / Raniplex / Ranisan / Ranitab / Ranitic / Ranitidin / Ranitin / Ranitine / Ranobel / Rantacid / Ranuber / Renatac / Sostril / Tanidina / Toriol / Ulcodin / Zandid / Zantic
Categories
UNII
884KT10YB7
CAS number
66357-35-5
Weight
Average: 314.404
Monoisotopic: 314.14126128
Chemical Formula
C13H22N4O3S
InChI Key
VMXUWOKSQNHOCA-UKTHLTGXSA-N
InChI
InChI=1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3/b13-9+
IUPAC Name
dimethyl[(5-{[(2-{[(E)-1-(methylamino)-2-nitroethenyl]amino}ethyl)sulfanyl]methyl}furan-2-yl)methyl]amine
SMILES
CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O

Pharmacology

Indication

Used in the treatment of peptic ulcer disease (PUD), dyspepsia, stress ulcer prophylaxis, and gastroesophageal reflux disease (GERD).

Associated Conditions
Pharmacodynamics

Ranitidine is a histamine H2-receptor antagonist similar to cimetidine and famotidine. An H2-receptor antagonist, often shortened to H2 antagonist, is a drug used to block the action of histamine on parietal cells in the stomach, decreasing acid production by these cells. These drugs are used in the treatment of dyspepsia, however their use has waned since the advent of the more effective proton pump inhibitors. Like the H1-antihistamines, the H2 antagonists are inverse agonists rather than true receptor antagonists.

Mechanism of action

The H2 antagonists are competitive inhibitors of histamine at the parietal cell H2 receptor. They suppress the normal secretion of acid by parietal cells and the meal-stimulated secretion of acid. They accomplish this by two mechanisms: histamine released by ECL cells in the stomach is blocked from binding on parietal cell H2 receptors which stimulate acid secretion, and other substances that promote acid secretion (such as gastrin and acetylcholine) have a reduced effect on parietal cells when the H2 receptors are blocked.

TargetActionsOrganism
AHistamine H2 receptor
antagonist
Human
UAcetylcholinesteraseNot AvailableHuman
UCholinesteraseNot AvailableHuman
Absorption

Approximately 50% bioavailability orally.

Volume of distribution
  • 1.4 L/kg
  • 1.76 L/kg [clinically significant renal function impairment (creatinine clearance 25 to 35 mL/min)]
Protein binding

15%

Metabolism

Hepatic. Ranitidine is metabolized to the N-oxide, S-oxide, and N-desmethyl metabolites, accounting for approximately 4%, 1%, and 1% of the dose, respectively.

Route of elimination

The principal route of excretion is the urine (active tubular excretion, renal clearance 410mL/min), with approximately 30% of the orally administered dose collected in the urine as unchanged drug in 24 hours.

Half life

2.8-3.1 hours

Clearance
  • 29 mL/min [clinically significant renal function impairment]
  • 3 mL/min/Kg [neonatal patients]
Toxicity

LD50=77mg/kg (orally in mice). Symptoms of overdose include muscular tremors, vomiting, and rapid respiration.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Ranitidine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative and stimulatory activities of Ranitidine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative and stimulatory activities of Ranitidine.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative and stimulatory activities of Ranitidine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative and stimulatory activities of Ranitidine.Experimental, Illicit
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Ranitidine.Approved, Investigational
AbirateroneThe serum concentration of Ranitidine can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Ranitidine.Approved, Investigational
AcetaminophenThe serum concentration of Ranitidine can be increased when it is combined with Acetaminophen.Approved
AcetohexamideThe serum concentration of Acetohexamide can be increased when it is combined with Ranitidine.Approved, Investigational, Withdrawn
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Ranitidine.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Ranitidine.Approved
AgmatineThe serum concentration of Agmatine can be increased when it is combined with Ranitidine.Experimental, Investigational
AlbendazoleThe serum concentration of Ranitidine can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Ranitidine.Experimental, Investigational
AlectinibThe serum concentration of Ranitidine can be increased when it is combined with Alectinib.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Ranitidine.Approved, Investigational
AlosetronThe metabolism of Ranitidine can be decreased when combined with Alosetron.Approved, Withdrawn
Aluminium clofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ranitidine is combined with Aluminium clofibrate.Experimental
AmantadineThe serum concentration of Ranitidine can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Ranitidine.Approved, Investigational
AmilorideThe serum concentration of Ranitidine can be increased when it is combined with Amiloride.Approved
Aminohippuric acidThe serum concentration of Ranitidine can be increased when it is combined with Aminohippuric acid.Approved, Investigational
AmiodaroneThe serum concentration of Ranitidine can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Ranitidine.Approved
AmlodipineThe serum concentration of Ranitidine can be increased when it is combined with Amlodipine.Approved
AmodiaquineThe serum concentration of Ranitidine can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineThe serum concentration of Ranitidine can be increased when it is combined with Amoxapine.Approved
AmphetamineAmphetamine may decrease the sedative and stimulatory activities of Ranitidine.Approved, Illicit, Investigational
AmprenavirThe serum concentration of Amprenavir can be increased when it is combined with Ranitidine.Approved, Investigational
AmsacrineThe serum concentration of Ranitidine can be increased when it is combined with Amsacrine.Approved, Investigational
AnnamycinThe serum concentration of Ranitidine can be increased when it is combined with Annamycin.Investigational
ApalutamideThe serum concentration of Ranitidine can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Ranitidine.Approved
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Ranitidine.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Ranitidine.Approved, Investigational
Ascorbic acidThe serum concentration of Ascorbic acid can be increased when it is combined with Ranitidine.Approved, Nutraceutical
AstemizoleThe serum concentration of Ranitidine can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Ranitidine.Approved, Investigational, Withdrawn
AtazanavirRanitidine can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Ranitidine.Approved
AvatrombopagThe serum concentration of Avatrombopag can be increased when it is combined with Ranitidine.Approved, Investigational
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Ranitidine.Approved, Investigational
AzelastineThe serum concentration of Ranitidine can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Ranitidine can be increased when it is combined with Azithromycin.Approved
Bafilomycin A1The serum concentration of Ranitidine can be increased when it is combined with Bafilomycin A1.Experimental
Bafilomycin B1The serum concentration of Ranitidine can be increased when it is combined with Bafilomycin B1.Experimental
BaricitinibThe serum concentration of Baricitinib can be increased when it is combined with Ranitidine.Approved, Investigational
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Ranitidine.Approved, Investigational
BenzphetamineBenzphetamine may decrease the sedative and stimulatory activities of Ranitidine.Approved, Illicit
BenzquinamideThe serum concentration of Ranitidine can be increased when it is combined with Benzquinamide.Withdrawn
Benzyl alcoholThe serum concentration of Ranitidine can be increased when it is combined with Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineRanitidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe serum concentration of Ranitidine can be increased when it is combined with Bepridil.Approved, Withdrawn
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Ranitidine.Approved, Investigational
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Ranitidine.Approved, Vet Approved
BezafibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ranitidine is combined with Bezafibrate.Approved, Investigational
BicalutamideThe serum concentration of Ranitidine can be increased when it is combined with Bicalutamide.Approved
Biricodar dicitrateThe serum concentration of Ranitidine can be increased when it is combined with Biricodar dicitrate.Investigational
BoceprevirThe serum concentration of Ranitidine can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Ranitidine can be decreased when combined with Bortezomib.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Ranitidine.Approved
Brefeldin AThe serum concentration of Ranitidine can be increased when it is combined with Brefeldin A.Experimental
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ranitidine.Approved, Investigational
BromocriptineThe serum concentration of Ranitidine can be increased when it is combined with Bromocriptine.Approved, Investigational
BromperidolThe serum concentration of Bromperidol can be increased when it is combined with Ranitidine.Approved, Investigational
BuprenorphineThe serum concentration of Ranitidine can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Ranitidine can be increased when it is combined with Bupropion.Approved
BuspironeThe serum concentration of Ranitidine can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Ranitidine.Approved
CaffeineThe serum concentration of Ranitidine can be increased when it is combined with Caffeine.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Ranitidine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Ranitidine.Approved
CaptoprilThe serum concentration of Ranitidine can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Ranitidine can be increased when combined with Carbamazepine.Approved, Investigational
CarbutamideThe serum concentration of Carbutamide can be increased when it is combined with Ranitidine.Experimental
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Ranitidine.Approved, Investigational
CarvedilolThe serum concentration of Ranitidine can be increased when it is combined with Carvedilol.Approved, Investigational
CefditorenRanitidine can cause a decrease in the absorption of Cefditoren resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
CefoperazoneThe serum concentration of Ranitidine can be increased when it is combined with Cefoperazone.Approved, Investigational
CefpodoximeRanitidine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CeftriaxoneThe serum concentration of Ranitidine can be increased when it is combined with Ceftriaxone.Approved
CefuroximeRanitidine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Ranitidine.Approved, Investigational
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Ranitidine.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Ranitidine.Approved, Withdrawn
Cerliponase alfaThe serum concentration of Cerliponase alfa can be increased when it is combined with Ranitidine.Approved, Investigational
ChlorambucilThe serum concentration of Chlorambucil can be increased when it is combined with Ranitidine.Approved
ChloroformThe serum concentration of Ranitidine can be increased when it is combined with Chloroform.Vet Approved
ChloroquineThe serum concentration of Chloroquine can be increased when it is combined with Ranitidine.Approved, Investigational, Vet Approved
ChlorphenamineThe serum concentration of Ranitidine can be increased when it is combined with Chlorphenamine.Approved
ChlorphentermineChlorphentermine may decrease the sedative and stimulatory activities of Ranitidine.Illicit, Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Ranitidine.Approved, Investigational, Vet Approved
ChlorpropamideThe serum concentration of Chlorpropamide can be increased when it is combined with Ranitidine.Approved, Investigational
ChlorprothixeneThe serum concentration of Ranitidine can be increased when it is combined with Chlorprothixene.Approved, Investigational, Withdrawn
CholineThe serum concentration of Choline can be increased when it is combined with Ranitidine.Approved, Nutraceutical
Choline salicylateThe serum concentration of Choline salicylate can be increased when it is combined with Ranitidine.Approved, Nutraceutical
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Ranitidine.Approved, Investigational
CiprofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ranitidine is combined with Ciprofibrate.Approved, Investigational
CiprofloxacinThe metabolism of Ranitidine can be decreased when combined with Ciprofloxacin.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Ranitidine.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Ranitidine.Approved
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Ranitidine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Ranitidine.Approved, Illicit
ClofazimineThe serum concentration of Ranitidine can be increased when it is combined with Clofazimine.Approved, Investigational
ClofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ranitidine is combined with Clofibrate.Approved, Investigational
ClofibrideThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ranitidine is combined with Clofibride.Experimental
ClomipramineThe serum concentration of Ranitidine can be increased when it is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Ranitidine.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Ranitidine.Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Ranitidine.Approved
CobicistatThe serum concentration of Ranitidine can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Ranitidine.Approved, Investigational
CocaineThe serum concentration of Ranitidine can be increased when it is combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Ranitidine.Approved
Concanamycin AThe serum concentration of Ranitidine can be increased when it is combined with Concanamycin A.Experimental
ConivaptanThe serum concentration of Ranitidine can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Ranitidine.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Ranitidine.Approved, Investigational
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Ranitidine.Approved
CurcuminThe serum concentration of Curcumin can be increased when it is combined with Ranitidine.Approved, Investigational
CyclosporineThe serum concentration of Ranitidine can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Ranitidine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
CysteamineRanitidine can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
CytarabineThe serum concentration of Cytarabine can be increased when it is combined with Ranitidine.Approved, Investigational
D-LevofloxacinThe serum concentration of Ranitidine can be increased when it is combined with D-Levofloxacin.Experimental
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Ranitidine.Approved
DabrafenibRanitidine can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DaclatasvirThe serum concentration of Ranitidine can be increased when it is combined with Daclatasvir.Approved, Investigational
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Ranitidine.Approved, Investigational
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Ranitidine.Approved
DasabuvirThe serum concentration of Dasabuvir can be increased when it is combined with Ranitidine.Approved
DasatinibRanitidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DaunorubicinThe serum concentration of Ranitidine can be increased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Ranitidine.Approved, Investigational
DeferasiroxThe serum concentration of Ranitidine can be increased when it is combined with Deferasirox.Approved, Investigational
DelavirdineRanitidine can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DesipramineThe serum concentration of Ranitidine can be increased when it is combined with Desipramine.Approved, Investigational
DesmethylsertralineThe serum concentration of Ranitidine can be increased when it is combined with Desmethylsertraline.Experimental
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Ranitidine.Approved, Investigational, Vet Approved
Dexchlorpheniramine maleateThe serum concentration of Ranitidine can be increased when it is combined with Dexchlorpheniramine maleate.Approved
DexmethylphenidateThe therapeutic efficacy of Dexmethylphenidate can be decreased when used in combination with Ranitidine.Approved, Investigational
DexniguldipineThe serum concentration of Ranitidine can be increased when it is combined with Dexniguldipine.Experimental
DextroamphetamineDextroamphetamine may decrease the sedative and stimulatory activities of Ranitidine.Approved, Illicit
DexverapamilThe serum concentration of Ranitidine can be increased when it is combined with Dexverapamil.Experimental
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Ranitidine.Approved, Illicit, Investigational, Vet Approved
Diethyl etherThe serum concentration of Ranitidine can be increased when it is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may decrease the sedative and stimulatory activities of Ranitidine.Approved, Illicit
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ranitidine.Approved, Investigational
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Ranitidine.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Ranitidine.Approved
DihydroergotamineThe serum concentration of Ranitidine can be increased when it is combined with Dihydroergotamine.Approved, Investigational
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Ranitidine.Approved, Investigational
DinoprostoneThe serum concentration of Ranitidine can be increased when it is combined with Dinoprostone.Approved
DiphenhydramineThe serum concentration of Ranitidine can be increased when it is combined with Diphenhydramine.Approved, Investigational
DipyridamoleThe serum concentration of Ranitidine can be increased when it is combined with Dipyridamole.Approved
DisopyramideThe serum concentration of Ranitidine can be increased when it is combined with Disopyramide.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Ranitidine.Approved, Investigational
DofequidarThe serum concentration of Ranitidine can be increased when it is combined with Dofequidar.Experimental, Investigational
DolutegravirThe serum concentration of Dolutegravir can be increased when it is combined with Ranitidine.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Ranitidine.Approved, Investigational, Vet Approved
DopamineThe serum concentration of Dopamine can be increased when it is combined with Ranitidine.Approved
DosulepinThe metabolism of Ranitidine can be decreased when combined with Dosulepin.Approved
DovitinibThe serum concentration of Ranitidine can be increased when it is combined with Dovitinib.Investigational
DoxazosinThe serum concentration of Ranitidine can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Ranitidine.Approved, Investigational
DoxofyllineThe serum concentration of Doxofylline can be increased when it is combined with Ranitidine.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Ranitidine.Approved, Investigational
DoxycyclineThe serum concentration of Doxycycline can be increased when it is combined with Ranitidine.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Ranitidine can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Ranitidine can be increased when it is combined with Dronedarone.Approved
DuloxetineThe serum concentration of Ranitidine can be increased when it is combined with Duloxetine.Approved
EconazoleThe serum concentration of Ranitidine can be increased when it is combined with Econazole.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Ranitidine.Approved
ElacridarThe serum concentration of Ranitidine can be increased when it is combined with Elacridar.Investigational
ElagolixThe serum concentration of Elagolix can be increased when it is combined with Ranitidine.Approved, Investigational
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Ranitidine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Ranitidine.Approved, Investigational
EmopamilThe serum concentration of Ranitidine can be increased when it is combined with Emopamil.Experimental
EnasidenibThe serum concentration of Ranitidine can be increased when it is combined with Enasidenib.Approved, Investigational
EnoxacinThe metabolism of Ranitidine can be decreased when combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Ranitidine can be increased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Ranitidine.Approved, Investigational
EpinephrineThe serum concentration of Epinephrine can be increased when it is combined with Ranitidine.Approved, Vet Approved
ErgonovineThe serum concentration of Ranitidine can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Ranitidine can be increased when it is combined with Ergotamine.Approved
ErlotinibRanitidine can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ErtugliflozinThe serum concentration of Ertugliflozin can be increased when it is combined with Ranitidine.Approved, Investigational
ErythromycinThe serum concentration of Ranitidine can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EsomeprazoleThe serum concentration of Ranitidine can be increased when it is combined with Esomeprazole.Approved, Investigational
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Ranitidine.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Estradiol acetate can be increased when it is combined with Ranitidine.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Estradiol benzoate can be increased when it is combined with Ranitidine.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be increased when it is combined with Ranitidine.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Estradiol dienanthate can be increased when it is combined with Ranitidine.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be increased when it is combined with Ranitidine.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Ranitidine can be increased when it is combined with Estramustine.Approved, Investigational
EstriolThe serum concentration of Estriol can be increased when it is combined with Ranitidine.Approved, Investigational, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Ranitidine.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ranitidine.Approved
EtofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ranitidine is combined with Etofibrate.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Ranitidine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Ranitidine.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Ranitidine.Approved
FamotidineThe serum concentration of Ranitidine can be increased when it is combined with Famotidine.Approved
FelodipineThe serum concentration of Ranitidine can be increased when it is combined with Felodipine.Approved, Investigational
FenofibrateThe serum concentration of Ranitidine can be increased when it is combined with Fenofibrate.Approved
Fenofibric acidThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ranitidine is combined with Fenofibric acid.Approved
FentanylThe serum concentration of Ranitidine can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
Ferric ammonium citrateRanitidine can cause a decrease in the absorption of Ferric ammonium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CarboxymaltoseRanitidine can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric cationRanitidine can cause a decrease in the absorption of Ferric cation resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric hydroxideRanitidine can cause a decrease in the absorption of Ferric hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferric oxideRanitidine can cause a decrease in the absorption of Ferric oxide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateRanitidine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferric subsulfateRanitidine can cause a decrease in the absorption of Ferric subsulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Ferric sulfateRanitidine can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous bisglycinateRanitidine can cause a decrease in the absorption of Ferrous bisglycinate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous chlorideRanitidine can cause a decrease in the absorption of Ferrous chloride resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferrous fumarateRanitidine can cause a decrease in the absorption of Ferrous fumarate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous gluconateRanitidine can cause a decrease in the absorption of Ferrous gluconate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous succinateRanitidine can cause a decrease in the absorption of Ferrous succinate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous sulfateRanitidine can cause a decrease in the absorption of Ferrous sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
FerumoxidesRanitidine can cause a decrease in the absorption of Ferumoxides resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FerumoxsilRanitidine can cause a decrease in the absorption of Ferumoxsil resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FerumoxytolRanitidine can cause a decrease in the absorption of Ferumoxytol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ranitidine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Ranitidine.Approved, Investigational
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Ranitidine.Approved
Fluciclovine (18F)The serum concentration of Fluciclovine (18F) can be increased when it is combined with Ranitidine.Approved
FluconazoleThe serum concentration of Ranitidine can be increased when it is combined with Fluconazole.Approved, Investigational
FluoxetineThe serum concentration of Ranitidine can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Flupentixol can be increased when it is combined with Ranitidine.Approved, Investigational, Withdrawn
FluphenazineThe serum concentration of Ranitidine can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Ranitidine can be increased when it is combined with Flurazepam.Approved, Illicit, Investigational
FluticasoneThe serum concentration of Fluticasone can be increased when it is combined with Ranitidine.Approved, Experimental, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Ranitidine.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Ranitidine.Approved
FluvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Ranitidine is combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Ranitidine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirRanitidine can cause a decrease in the absorption of Fosamprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FurosemideThe excretion of Ranitidine can be decreased when combined with Furosemide.Approved, Vet Approved
GallopamilThe serum concentration of Ranitidine can be increased when it is combined with Gallopamil.Investigational
GefitinibRanitidine can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GemfibrozilThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ranitidine is combined with Gemfibrozil.Approved
GenisteinThe serum concentration of Ranitidine can be increased when it is combined with Genistein.Investigational
GepefrineGepefrine may decrease the sedative and stimulatory activities of Ranitidine.Experimental
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Ranitidine.Approved, Investigational
GleptoferronRanitidine can cause a decrease in the absorption of Gleptoferron resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
GlibornurideThe serum concentration of Glibornuride can be increased when it is combined with Ranitidine.Investigational, Withdrawn
GliclazideThe serum concentration of Gliclazide can be increased when it is combined with Ranitidine.Approved
GlimepirideThe serum concentration of Glimepiride can be increased when it is combined with Ranitidine.Approved
GlipizideThe serum concentration of Glipizide can be increased when it is combined with Ranitidine.Approved, Investigational
GliquidoneThe serum concentration of Gliquidone can be increased when it is combined with Ranitidine.Approved, Investigational
GlisoxepideThe serum concentration of Glisoxepide can be increased when it is combined with Ranitidine.Investigational
GlycerinThe serum concentration of Ranitidine can be increased when it is combined with Glycerin.Approved, Investigational
Gramicidin DThe serum concentration of Gramicidin D can be increased when it is combined with Ranitidine.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Ranitidine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Ranitidine.Approved, Investigational, Withdrawn
GuanidineThe serum concentration of Ranitidine can be increased when it is combined with Guanidine.Approved
HistamineThe serum concentration of Histamine can be increased when it is combined with Ranitidine.Approved, Investigational
HM-30181The serum concentration of Ranitidine can be increased when it is combined with HM-30181.Experimental
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ranitidine.Approved, Investigational
HycanthoneThe serum concentration of Ranitidine can be increased when it is combined with Hycanthone.Approved, Investigational
HydrocodoneThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Ranitidine resulting in a loss in efficacy.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Ranitidine.Approved, Vet Approved
HydroxyamphetamineHydroxyamphetamine may decrease the sedative and stimulatory activities of Ranitidine.Approved
HydroxychloroquineThe serum concentration of Ranitidine can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyureaThe serum concentration of Hydroxyurea can be increased when it is combined with Ranitidine.Approved
IbuprofenThe serum concentration of Ranitidine can be increased when it is combined with Ibuprofen.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Ranitidine.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Ranitidine.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Ranitidine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Ranitidine.Approved
IndinavirRanitidine can cause a decrease in the absorption of Indinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IndomethacinThe serum concentration of Ranitidine can be increased when it is combined with Indomethacin.Approved, Investigational
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Ranitidine.Approved, Investigational
Iofetamine I-123Iofetamine I-123 may decrease the sedative and stimulatory activities of Ranitidine.Approved
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Ranitidine.Approved, Investigational
IronRanitidine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranRanitidine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron isomaltoside 1000Ranitidine can cause a decrease in the absorption of Iron isomaltoside 1000 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Iron saccharateRanitidine can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsavuconazoniumThe serum concentration of Ranitidine can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsradipineThe serum concentration of Ranitidine can be increased when it is combined with Isradipine.Approved, Investigational
ItraconazoleRanitidine can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
IvacaftorThe serum concentration of Ranitidine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Ranitidine.Approved, Investigational, Vet Approved
IvosidenibThe serum concentration of Ivosidenib can be increased when it is combined with Ranitidine.Approved, Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Ranitidine.Approved
KetoconazoleRanitidine can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Ranitidine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Ranitidine.Approved, Investigational
LaniquidarThe serum concentration of Ranitidine can be increased when it is combined with Laniquidar.Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Ranitidine.Approved, Investigational
LapatinibThe serum concentration of Ranitidine can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirRanitidine can cause a decrease in the absorption of Ledipasvir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Ranitidine.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Ranitidine.Approved, Investigational
LetermovirThe serum concentration of Letermovir can be increased when it is combined with Ranitidine.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Ranitidine.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Ranitidine.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Ranitidine.Approved, Investigational
LidocaineThe serum concentration of Ranitidine can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Ranitidine.Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative and stimulatory activities of Ranitidine.Approved, Investigational
LobeglitazoneThe metabolism of Ranitidine can be decreased when combined with Lobeglitazone.Approved, Investigational
LomerizineThe serum concentration of Ranitidine can be increased when it is combined with Lomerizine.Experimental
LomitapideThe serum concentration of Ranitidine can be increased when it is combined with Lomitapide.Approved, Investigational
LonafarnibThe serum concentration of Ranitidine can be increased when it is combined with Lonafarnib.Investigational
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Ranitidine.Approved
LopinavirThe serum concentration of Ranitidine can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Ranitidine can be increased when it is combined with Loratadine.Approved, Investigational
LosartanThe serum concentration of Losartan can be increased when it is combined with Ranitidine.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Ranitidine.Approved, Investigational
LoxapineThe serum concentration of Ranitidine can be increased when it is combined with Loxapine.Approved
LumacaftorThe serum concentration of Ranitidine can be decreased when it is combined with Lumacaftor.Approved
MefloquineThe serum concentration of Ranitidine can be increased when it is combined with Mefloquine.Approved, Investigational
Megestrol acetateThe serum concentration of Ranitidine can be increased when it is combined with Megestrol acetate.Approved, Investigational, Vet Approved
MelphalanThe serum concentration of Melphalan can be increased when it is combined with Ranitidine.Approved
MemantineThe serum concentration of Memantine can be increased when it is combined with Ranitidine.Approved, Investigational
MephedroneMephedrone may decrease the sedative and stimulatory activities of Ranitidine.Investigational
MephentermineMephentermine may decrease the sedative and stimulatory activities of Ranitidine.Approved
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Ranitidine.Approved
MetahexamideThe serum concentration of Metahexamide can be increased when it is combined with Ranitidine.Experimental
MetforminThe serum concentration of Metformin can be increased when it is combined with Ranitidine.Approved
MethadoneThe serum concentration of Ranitidine can be increased when it is combined with Methadone.Approved
MethamphetamineMethamphetamine may decrease the sedative and stimulatory activities of Ranitidine.Approved, Illicit
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Ranitidine.Approved
MethoxyphenamineMethoxyphenamine may decrease the sedative and stimulatory activities of Ranitidine.Experimental
MethylphenidateThe therapeutic efficacy of Methylphenidate can be decreased when used in combination with Ranitidine.Approved, Investigational
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Ranitidine.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Ranitidine.Approved, Investigational
MetronidazoleThe serum concentration of Ranitidine can be increased when it is combined with Metronidazole.Approved
MevastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Ranitidine is combined with Mevastatin.Experimental
MexiletineThe metabolism of Ranitidine can be decreased when combined with Mexiletine.Approved, Investigational
MibefradilThe serum concentration of Ranitidine can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Ranitidine can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Ranitidine can be increased when it is combined with Midazolam.Approved, Illicit
MidomafetamineMidomafetamine may decrease the sedative and stimulatory activities of Ranitidine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Ranitidine can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Ranitidine can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Ranitidine.Approved
MitomycinThe serum concentration of Mitomycin can be increased when it is combined with Ranitidine.Approved
MitotaneThe serum concentration of Ranitidine can be increased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Ranitidine can be increased when it is combined with Mitoxantrone.Approved, Investigational
MMDAMMDA may decrease the sedative and stimulatory activities of Ranitidine.Experimental, Illicit
MonensinThe serum concentration of Ranitidine can be increased when it is combined with Monensin.Vet Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Ranitidine.Approved, Investigational
MoxidectinThe serum concentration of Moxidectin can be increased when it is combined with Ranitidine.Approved, Investigational, Vet Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ranitidine.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Ranitidine.Approved
NafamostatThe serum concentration of Nafamostat can be increased when it is combined with Ranitidine.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Ranitidine.Approved
NelfinavirRanitidine can cause a decrease in the absorption of Nelfinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NeostigmineThe serum concentration of Neostigmine can be increased when it is combined with Ranitidine.Approved, Vet Approved
NeratinibThe serum concentration of Ranitidine can be increased when it is combined with Neratinib.Approved, Investigational
NicardipineThe serum concentration of Ranitidine can be increased when it is combined with Nicardipine.Approved, Investigational
NicotineThe serum concentration of Ranitidine can be increased when it is combined with Nicotine.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Ranitidine.Approved
NigericinThe serum concentration of Ranitidine can be increased when it is combined with Nigericin.Experimental
NiguldipineThe serum concentration of Ranitidine can be increased when it is combined with Niguldipine.Experimental
NilotinibRanitidine can cause a decrease in the absorption of Nilotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NimodipineThe serum concentration of Ranitidine can be increased when it is combined with Nimodipine.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Ranitidine.Approved
NisoldipineThe serum concentration of Ranitidine can be increased when it is combined with Nisoldipine.Approved
NitrendipineThe serum concentration of Ranitidine can be increased when it is combined with Nitrendipine.Approved, Investigational
NitroprussideRanitidine can cause a decrease in the absorption of Nitroprusside resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Ranitidine.Approved
NorepinephrineThe serum concentration of Norepinephrine can be increased when it is combined with Ranitidine.Approved
OctreotideThe serum concentration of Octreotide can be increased when it is combined with Ranitidine.Approved, Investigational
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Ranitidine.Investigational
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Ranitidine.Approved, Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Ranitidine.Approved, Investigational
OmeprazoleThe serum concentration of Omeprazole can be increased when it is combined with Ranitidine.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Ondansetron can be increased when it is combined with Ranitidine.Approved
ONT-093The serum concentration of Ranitidine can be increased when it is combined with ONT-093.Investigational
OsimertinibThe serum concentration of Ranitidine can be decreased when it is combined with Osimertinib.Approved
OxaliplatinThe serum concentration of Oxaliplatin can be increased when it is combined with Ranitidine.Approved, Investigational
OxprenololThe serum concentration of Ranitidine can be increased when it is combined with Oxprenolol.Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Ranitidine.Approved, Vet Approved
PaliperidoneThe serum concentration of Paliperidone can be increased when it is combined with Ranitidine.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Ranitidine.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be increased when it is combined with Ranitidine.Approved
ParitaprevirThe serum concentration of Paritaprevir can be increased when it is combined with Ranitidine.Approved, Investigational
ParoxetineThe serum concentration of Ranitidine can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Ranitidine.Approved
Peginterferon alfa-2bThe serum concentration of Ranitidine can be increased when it is combined with Peginterferon alfa-2b.Approved
PentazocineThe serum concentration of Pentazocine can be increased when it is combined with Ranitidine.Approved, Vet Approved
PerflubutaneRanitidine can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PethidineThe serum concentration of Ranitidine can be increased when it is combined with Pethidine.Approved
PhenforminThe serum concentration of Ranitidine can be increased when it is combined with Phenformin.Approved, Investigational, Withdrawn
PhenobarbitalThe metabolism of Ranitidine can be increased when combined with Phenobarbital.Approved, Investigational
PhenothiazineThe serum concentration of Phenothiazine can be increased when it is combined with Ranitidine.Vet Approved
PhenoxybenzamineThe serum concentration of Ranitidine can be increased when it is combined with Phenoxybenzamine.Approved
PhenterminePhentermine may decrease the sedative and stimulatory activities of Ranitidine.Approved, Illicit
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Ranitidine.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Ranitidine.Approved, Investigational
PimagedineThe serum concentration of Ranitidine can be increased when it is combined with Pimagedine.Investigational
PimozideThe serum concentration of Ranitidine can be increased when it is combined with Pimozide.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Ranitidine.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Ranitidine.Approved, Investigational
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Ranitidine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Ranitidine.Approved, Investigational
PosaconazoleThe serum concentration of Ranitidine can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe serum concentration of Pramipexole can be increased when it is combined with Ranitidine.Approved, Investigational
PrasugrelThe serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Ranitidine resulting in a loss in efficacy.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Ranitidine.Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Ranitidine.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Ranitidine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Ranitidine.Approved, Vet Approved
PrimaquineThe serum concentration of Ranitidine can be increased when it is combined with Primaquine.Approved
PrimidoneThe metabolism of Ranitidine can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Ranitidine can be increased when it is combined with Probenecid.Approved, Investigational
ProgesteroneThe serum concentration of Ranitidine can be increased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Ranitidine can be increased when it is combined with Promethazine.Approved, Investigational
PropafenoneThe serum concentration of Ranitidine can be increased when it is combined with Propafenone.Approved
PropofolThe serum concentration of Ranitidine can be increased when it is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Ranitidine.Approved, Investigational
ProtriptylineThe serum concentration of Ranitidine can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Ranitidine.Approved
Prussian blueRanitidine can cause a decrease in the absorption of Prussian blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PseudoephedrinePseudoephedrine may decrease the sedative and stimulatory activities of Ranitidine.Approved
QuercetinThe serum concentration of Ranitidine can be increased when it is combined with Quercetin.Experimental, Investigational
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Ranitidine.Approved
QuinacrineThe serum concentration of Ranitidine can be increased when it is combined with Quinacrine.Approved, Investigational
QuinidineThe serum concentration of Ranitidine can be increased when it is combined with Quinidine.Approved, Investigational
QuinineThe serum concentration of Ranitidine can be increased when it is combined with Quinine.Approved
ReboxetineThe serum concentration of Ranitidine can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Ranitidine.Approved
ReserpineThe serum concentration of Ranitidine can be increased when it is combined with Reserpine.Approved, Investigational
Reversin 121The serum concentration of Ranitidine can be increased when it is combined with Reversin 121.Experimental
Rhodamine 6GThe serum concentration of Rhodamine 6G can be increased when it is combined with Ranitidine.Experimental
RifampicinThe metabolism of Ranitidine can be increased when combined with Rifampicin.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Ranitidine.Approved, Investigational
RilpivirineRanitidine can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RisedronateRanitidine can cause an increase in the absorption of Risedronate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
RitobegronRitobegron may decrease the sedative and stimulatory activities of Ranitidine.Investigational
RitonavirThe serum concentration of Ranitidine can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Ranitidine.Approved
RolapitantThe serum concentration of Ranitidine can be increased when it is combined with Rolapitant.Approved, Investigational
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Ranitidine.Approved, Investigational
RonifibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ranitidine is combined with Ronifibrate.Experimental
RopiniroleThe metabolism of Ranitidine can be decreased when combined with Ropinirole.Approved, Investigational
RosuvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Ranitidine is combined with Rosuvastatin.Approved
RucaparibThe serum concentration of Rucaparib can be increased when it is combined with Ranitidine.Approved, Investigational
SalinomycinThe serum concentration of Ranitidine can be increased when it is combined with Salinomycin.Vet Approved
SaquinavirRanitidine can cause an increase in the absorption of Saquinavir resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Ranitidine.Approved
SertralineThe serum concentration of Ranitidine can be increased when it is combined with Sertraline.Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Ranitidine.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Ranitidine.Approved
SimfibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ranitidine is combined with Simfibrate.Experimental
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Ranitidine.Approved
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Ranitidine.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Ranitidine.Approved, Investigational
Sodium feredetateRanitidine can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Ranitidine.Approved
SomatostatinThe serum concentration of Somatostatin can be increased when it is combined with Ranitidine.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Ranitidine.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Ranitidine.Approved, Investigational
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Ranitidine.Experimental
StanoloneThe serum concentration of Stanolone can be increased when it is combined with Ranitidine.Illicit, Investigational
Stanolone acetateThe serum concentration of Stanolone acetate can be increased when it is combined with Ranitidine.Experimental
StaurosporineThe serum concentration of Ranitidine can be increased when it is combined with Staurosporine.Experimental
SumatriptanThe serum concentration of Sumatriptan can be increased when it is combined with Ranitidine.Approved, Investigational
SunitinibThe serum concentration of Sunitinib can be increased when it is combined with Ranitidine.Approved, Investigational
SuvorexantThe serum concentration of Ranitidine can be increased when it is combined with Suvorexant.Approved, Investigational
TacrineThe serum concentration of Tacrine can be increased when it is combined with Ranitidine.Investigational, Withdrawn
TacrolimusThe serum concentration of Ranitidine can be increased when it is combined with Tacrolimus.Approved, Investigational
TafenoquineThe serum concentration of Ranitidine can be increased when it is combined with Tafenoquine.Approved, Investigational
TalinololThe serum concentration of Talinolol can be increased when it is combined with Ranitidine.Investigational
TamoxifenThe serum concentration of Ranitidine can be increased when it is combined with Tamoxifen.Approved
TariquidarThe serum concentration of Ranitidine can be increased when it is combined with Tariquidar.Investigational
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Ranitidine.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Ranitidine.Approved, Investigational
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Ranitidine.Approved, Withdrawn
TelmisartanThe serum concentration of Ranitidine can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Ranitidine.Approved
TeniposideThe serum concentration of Teniposide can be increased when it is combined with Ranitidine.Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Ranitidine.Approved, Withdrawn
TeriflunomideThe serum concentration of Ranitidine can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Ranitidine can be increased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Ranitidine can be increased when it is combined with Testosterone.Approved, Investigational
Testosterone cypionateThe serum concentration of Ranitidine can be increased when it is combined with Testosterone cypionate.Approved
Testosterone enanthateThe serum concentration of Ranitidine can be increased when it is combined with Testosterone enanthate.Approved
Testosterone propionateThe serum concentration of Testosterone propionate can be increased when it is combined with Ranitidine.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe serum concentration of Ranitidine can be increased when it is combined with Testosterone undecanoate.Approved, Investigational
TetracyclineThe serum concentration of Tetracycline can be increased when it is combined with Ranitidine.Approved, Vet Approved
TetraethylammoniumThe serum concentration of Tetraethylammonium can be increased when it is combined with Ranitidine.Experimental, Investigational
Tetraferric tricitrate decahydrateRanitidine can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TetrandrineThe serum concentration of Ranitidine can be increased when it is combined with Tetrandrine.Experimental
TheophyllineThe metabolism of Ranitidine can be decreased when combined with Theophylline.Approved
ThiamineThe serum concentration of Ranitidine can be increased when it is combined with Thiamine.Approved, Investigational, Nutraceutical, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Ranitidine.Approved, Withdrawn
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Ranitidine.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Ranitidine.Approved
TipifarnibThe serum concentration of Ranitidine can be increased when it is combined with Tipifarnib.Investigational
TipiracilThe serum concentration of Tipiracil can be increased when it is combined with Ranitidine.Approved, Investigational
TipranavirThe serum concentration of Ranitidine can be increased when it is combined with Tipranavir.Approved, Investigational
TolazamideThe serum concentration of Tolazamide can be increased when it is combined with Ranitidine.Approved, Investigational
TolbutamideThe serum concentration of Tolbutamide can be increased when it is combined with Ranitidine.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Ranitidine.Approved
TopiramateThe serum concentration of Topiramate can be increased when it is combined with Ranitidine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Ranitidine.Approved, Investigational
ToremifeneThe serum concentration of Ranitidine can be increased when it is combined with Toremifene.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Ranitidine.Approved, Investigational
TrifluoperazineThe serum concentration of Trifluoperazine can be increased when it is combined with Ranitidine.Approved, Investigational
TriflupromazineThe serum concentration of Ranitidine can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Ranitidine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Ranitidine.Approved
TroleandomycinThe serum concentration of Ranitidine can be increased when it is combined with Troleandomycin.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Ranitidine.Approved, Investigational, Nutraceutical
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Ranitidine.Approved
ValinomycinThe serum concentration of Valinomycin can be increased when it is combined with Ranitidine.Experimental
ValspodarThe serum concentration of Valspodar can be increased when it is combined with Ranitidine.Investigational
VareniclineRanitidine may decrease the excretion rate of Varenicline which could result in a higher serum level.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Ranitidine.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Ranitidine.Approved, Investigational
VemurafenibThe serum concentration of Ranitidine can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Ranitidine.Approved, Investigational
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Ranitidine.Approved
VerapamilThe serum concentration of Ranitidine can be increased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Ranitidine.Approved
VincristineThe excretion of Vincristine can be decreased when combined with Ranitidine.Approved, Investigational
VinflunineThe serum concentration of Vinflunine can be increased when it is combined with Ranitidine.Approved, Investigational
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Ranitidine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Ranitidine.Approved, Investigational
VoacamineThe serum concentration of Ranitidine can be increased when it is combined with Voacamine.Approved, Investigational
VorapaxarThe serum concentration of Ranitidine can be increased when it is combined with Vorapaxar.Approved
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Ranitidine.Approved, Investigational
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Ranitidine.Approved
YohimbineThe serum concentration of Ranitidine can be increased when it is combined with Yohimbine.Approved, Investigational, Vet Approved
ZafirlukastThe metabolism of Ranitidine can be decreased when combined with Zafirlukast.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Ranitidine.Approved
ZomepiracThe serum concentration of Ranitidine can be increased when it is combined with Zomepirac.Withdrawn
ZosuquidarThe serum concentration of Ranitidine can be increased when it is combined with Zosuquidar.Investigational
ZucapsaicinThe metabolism of Ranitidine can be decreased when combined with Zucapsaicin.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication.
  • Take without regard to meals.

References

Synthesis Reference

John W. Clitherow, "Intermediates in the preparation of ranitidine." U.S. Patent US4413135, issued November, 1981.

US4413135
General References
Not Available
External Links
Human Metabolome Database
HMDB0001930
KEGG Drug
D00422
PubChem Compound
3001055
PubChem Substance
46505543
ChemSpider
2272523
BindingDB
50103506
ChEBI
8776
ChEMBL
CHEMBL512
Therapeutic Targets Database
DAP000340
PharmGKB
PA451224
IUPHAR
1234
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Ranitidine
ATC Codes
A02BA07 — Ranitidine bismuth citrateA02BA02 — Ranitidine
AHFS Codes
  • 56:28.12 — Histamine H2-antagonists
FDA label
Download (247 KB)
MSDS
Download (73.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableAutonomic Failure / Idiopathic orthostatic hypotension1
1CompletedBasic Science(t1/2,λz) / Cmax / Pharmacokinetics / Plasma [AUC(0-672)] / Plasma [AUC(0-t)] / Plasma AUC / Tmax1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic SciencePharmacokinetics1
1CompletedBasic ScienceReflux Esophagitis (RE)1
1CompletedTreatmentHealthy Volunteers5
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1RecruitingBasic ScienceChronic Obstructive Pulmonary Disease (COPD) / Heart Failure, Unspecified / High Blood Pressure (Hypertension) / Pulmonary Arterial Hypertension (PAH)1
1TerminatedOtherHealthy Volunteers1
2CompletedDiagnosticGastroesophageal Reflux Disease / Reflux, Gastroesophageal1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentRenal Cell Adenocarcinoma1
2Not Yet RecruitingPreventionPost Anaesthetic Shivering1
2RecruitingTreatmentPlasma Cell Myeloma1
2RecruitingTreatmentPostpartum Hemorrhage1
2TerminatedTreatmentHyper IgE Syndromes / Hyper-IgE Recurrent Infection Syndrome / Immune Deficiencies1
2TerminatedTreatmentT-cell Type Acute Leukemia-Precursor T-lymphoblastic Lymphoma/Leukaemia1
2, 3CompletedTreatmentHelicobacter Pylori [H. Pylori] as the Cause of Diseases1
3CompletedTreatmentGastric Ulcer (GU)1
3CompletedTreatmentGastro-esophageal Reflux Disease (GERD)2
3CompletedTreatmentNSAID Associated Gastric Ulcers2
3CompletedTreatmentReflux, Gastroesophageal1
3RecruitingTreatmentDisseminated Sclerosis1
3TerminatedHealth Services ResearchCoughing1
3TerminatedTreatmentEsophageal Metaplasia1
4CompletedTreatmentAntimicrobial Drug Susceptibility Pattern / Etiological Organisms / Stress Ulcer Prophylaxis / Ventilator-associated Bacterial Pneumonia1
4CompletedTreatmentCoronary Artery Disease / Drug Interaction Potentiation / VA Drug Interactions [VA Drug Interaction]1
4CompletedTreatmentCritically Ill Patients / Indication for Stress Ulcer Prophylaxis1
4CompletedTreatmentIndigestion2
4CompletedTreatmentProstate Cancer1
4CompletedTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)1
4Enrolling by InvitationTreatmentAnesthesia Complication / Hemodynamics Instability / Ileus paralytic / Nausea / Postoperative pain / Vomiting1
4Not Yet RecruitingBasic ScienceCancers1
4RecruitingTreatmentWet Macular Degeneration1
4WithdrawnPreventionPeptic Ulcers1
4WithdrawnTreatmentEustachian Tube Dysfunction / Laryngopharyngeal Reflux1
Not AvailableCompletedNot AvailableCommunity Acquired Pneumonia (CAP) / Gastro-esophageal Reflux Disease (GERD)1
Not AvailableCompletedNot AvailablePharmacokinetics / Voriconazole1
Not AvailableCompletedNot AvailableStrokes1
Not AvailableCompletedSupportive CareAntiplatelet Effect1
Not AvailableCompletedTreatmentGastrointestinal Diseases / Indigestion1
Not AvailableUnknown StatusPreventionPoisoning1

Pharmacoeconomics

Manufacturers
  • Dr reddys laboratories ltd
  • Genpharm inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Glaxosmithkline
  • Bedford laboratories div ben venue laboratories inc
  • Ben venue laboratories inc
  • Alpharma us pharmaceuticals division
  • Amneal pharmaceuticals
  • Apotex inc
  • Aurobindo pharma usa inc
  • Cypress pharmaceutical inc
  • Pharmaceutical assoc inc div beach products
  • Ranbaxy laboratories ltd
  • Vintage pharmaceuticals inc
  • Wockhardt ltd
  • Boehringer ingelheim pharmaceuticals inc
  • Amneal pharmaceuticals ny llc
  • Boehringer ingelheim corp
  • Contract pharmacal corp
  • Dr reddys laboratories inc
  • Glenmark generics inc usa
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • L perrigo co
  • Ranbaxy pharmaceuticals inc
  • Torpharm inc
  • Watson laboratories inc
  • Wockhardt americas inc
  • Boehringer ingelheim
Packagers
  • Actavis Group
  • Advanced Pharmaceutical Services Inc.
  • Aidarex Pharmacuticals LLC
  • Amerisource Health Services Corp.
  • Amneal Pharmaceuticals
  • Apotex Inc.
  • Apotheca Inc.
  • Apothecon
  • AQ Pharmaceuticals Inc.
  • A-S Medication Solutions LLC
  • Banner Pharmacaps Inc.
  • Bedford Labs
  • Ben Venue Laboratories Inc.
  • Blenheim Pharmacal
  • Boehringer Ingelheim Ltd.
  • Bryant Ranch Prepack
  • Cardinal Health
  • Central Texas Community Health Centers
  • Chain Drug
  • Cobalt Pharmaceuticals Inc.
  • Comprehensive Consultant Services Inc.
  • Corepharma LLC
  • Coupler Enterprises Inc.
  • CVS Pharmacy
  • Dept Health Central Pharmacy
  • DHHS Program Support Center Supply Service Center
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Doctor Reddys Laboratories Ltd.
  • DSM Corp.
  • Fusion Pharmaceuticals LLC
  • Genpharm LP
  • GlaxoSmithKline Inc.
  • Glenmark Generics Ltd.
  • Golden State Medical Supply Inc.
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Hospira Inc.
  • Innovative Manufacturing and Distribution Services Inc.
  • Innoviant Pharmacy Inc.
  • Ivax Pharmaceuticals
  • Kaiser Foundation Hospital
  • Keltman Pharmaceuticals Inc.
  • Lake Erie Medical and Surgical Supply
  • Liberty Pharmaceuticals
  • Major Pharmaceuticals
  • Mckesson Corp.
  • Medisca Inc.
  • Medvantx Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Novopharm Ltd.
  • Nucare Pharmaceuticals Inc.
  • Ohm Laboratories Inc.
  • Palmetto Pharmaceuticals Inc.
  • Par Pharmaceuticals
  • Patheon Inc.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Penn Labs
  • Perrigo Co.
  • Pharmaceutical Association
  • Pharmaceutical Packaging Center
  • Pharmedix
  • Physicians Total Care Inc.
  • Precision Dose Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Prescription Dispensing Service Inc.
  • Prx Pharmaceuticals
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Roxane Labs
  • Sandhills Packaging Inc.
  • Sandoz
  • Shasun Chemicals & Drugs Ltd.
  • Southwood Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Sunmark
  • Teva Pharmaceutical Industries Ltd.
  • Torpharm Inc.
  • Tya Pharmaceuticals
  • UDL Laboratories
  • Va Cmop Dallas
  • Vangard Labs Inc.
  • Vistapharm Inc.
  • Walgreen Co.
  • Watson Pharmaceuticals
  • Wockhardt Ltd.
  • Xactdose Inc.
Dosage forms
FormRouteStrength
TabletOral75.0 mg
TabletOral150 mg/1
Kit
Kit
Tablet, film coatedOral150 mg/1
Tablet, coatedOral150 mg/1
TabletOral400 mg
SolutionOral15 mg/mL
SolutionOral150 mg/mL
SyrupOral15 mg/mL
SyrupTopical15 mg/mL
TabletOral300 mg/1
Tablet, coatedOral75 mg/1
Tablet, film coatedOral300 mg/1
Tablet, film coatedOral75 mg/1
CapsuleOral150 mg/1
CapsuleOral300 mg/1
InjectionIntramuscular; Intravenous25 mg/mL
SolutionOral150 mg/10mL
SolutionOral75 mg/5mL
TabletOral75 mg
TabletOral150 mg
TabletOral300 mg
SolutionIntramuscular; Intravenous25 mg
SolutionOral75 mg
TabletOral75 mg/1
Injection, solutionIntramuscular; Intravenous25 mg/mL
LiquidIntramuscular; Intravenous25 mg
SolutionIntramuscular; Intravenous50 mg
SolutionOral15 mg
CapsuleOral150 mg
CapsuleOral300 mg
Prices
Unit descriptionCostUnit
Zantac 300 mg tablet7.96USD tablet
Ranitidine hcl powder5.2USD g
Zantac EFFERdose 25 mg Effervescent Tabs4.18USD tab
Zantac 25 efferdose tablet4.02USD tablet
Zantac 150 mg tablet3.11USD tablet
Ranitidine HCl 300 mg capsule2.85USD capsule
Ranitidine HCl 300 mg tablet2.79USD tablet
Ranitidine 300 mg tablet2.69USD tablet
Ranitidine hcl 25 mg/ml vial2.0USD ml
Zantac 25 mg/ml vial2.0USD ml
Ranitidine HCl 150 mg capsule1.58USD capsule
Zantac 25 mg/ml1.58USD ml
Ranitidine HCl 150 mg tablet1.54USD tablet
Ranitidine 150 mg tablet1.48USD tablet
Ranitidine 25 mg/ml1.26USD ml
Ranitidine HCl 15 mg/ml Syrup1.0USD ml
Ratio-Ranitidine 300 mg Tablet0.82USD tablet
Apo-Ranitidine 300 mg Tablet0.82USD tablet
Co Ranitidine 300 mg Tablet0.82USD tablet
Mylan-Ranitidine 300 mg Tablet0.82USD tablet
Nu-Ranit 300 mg Tablet0.82USD tablet
Pms-Ranitidine 300 mg Tablet0.82USD tablet
Ran-Ranitidine 300 mg Tablet0.82USD tablet
Zantac 15 mg/ml Syrup0.81USD ml
Zantac 75 tablet0.49USD tablet
Apo-Ranitidine 150 mg Tablet0.42USD tablet
Co Ranitidine 150 mg Tablet0.42USD tablet
Mylan-Ranitidine 150 mg Tablet0.42USD tablet
Nu-Ranit 150 mg Tablet0.42USD tablet
Pms-Ranitidine 150 mg Tablet0.42USD tablet
Ran-Ranitidine 150 mg Tablet0.42USD tablet
Ratio-Ranitidine 150 mg Tablet0.42USD tablet
Novo-Ranidine 300 mg Tablet0.38USD tablet
Phl-Ranitidine 300 mg Tablet0.38USD tablet
Sandoz Ranitidine 300 mg Tablet0.38USD tablet
Zantac 300 mg Tablet0.38USD tablet
Zantac 75 mg tablet0.28USD tablet
Wal-zan 75 mg tablet0.27USD tablet
Zantac 15 mg/ml Solution0.23USD ml
Ranitidine hcl 75 mg tablet0.22USD tablet
Sm acid reducer 75 mg tablet0.22USD tablet
Acid reducer 150 mg tablet0.2USD tablet
Wal-zan 75 tablet0.2USD tablet
Novo-Ranidine 150 mg Tablet0.19USD tablet
Phl-Ranitidine 150 mg Tablet0.19USD tablet
Sandoz Ranitidine 150 mg Tablet0.19USD tablet
Zantac 150 mg Tablet0.19USD tablet
CVS Pharmacy ranitidine 75 mg tablet0.15USD tablet
Apo-Ranitidine 15 mg/ml Solution0.12USD ml
Novo-Ranidine 15 mg/ml Solution0.12USD ml
Acid reducer 75 mg tablet0.11USD tablet
CVS Pharmacy acid reducer 75 mg tablet0.11USD tablet
Qc ranitidine 75 mg tablet0.07USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5098715No1993-12-202010-12-20Us
US5102665No1992-12-232009-12-23Us
CA1332610No1994-10-182011-10-18Canada

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)69-70 °CPhysProp
water solubility24.7 mg/mLNot Available
logP0.27SANGSTER (1993)
Caco2 permeability-6.31ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0795 mg/mLALOGPS
logP0.79ALOGPS
logP0.98ChemAxon
logS-3.6ALOGPS
pKa (Strongest Basic)8.08ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area86.26 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity95.15 m3·mol-1ChemAxon
Polarizability33.58 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9936
Blood Brain Barrier-0.8783
Caco-2 permeable-0.5838
P-glycoprotein substrateSubstrate0.8527
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.8893
Renal organic cation transporterNon-inhibitor0.8177
CYP450 2C9 substrateNon-substrate0.7702
CYP450 2D6 substrateSubstrate0.7414
CYP450 3A4 substrateNon-substrate0.5565
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7819
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8077
BiodegradationNot ready biodegradable0.9249
Rat acute toxicity2.0903 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.8628
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
MS/MS Spectrum - Quattro_QQQ 10V, PositiveLC-MS/MSsplash10-01ot-7906000000-d0c73cd55f0c88b5292c
MS/MS Spectrum - Quattro_QQQ 25V, PositiveLC-MS/MSsplash10-004j-2900000000-72810aa2bdb337010c71
MS/MS Spectrum - Quattro_QQQ 40V, PositiveLC-MS/MSsplash10-0f92-3900000000-4984706aec6a10a3a701
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, NegativeLC-MS/MSsplash10-03di-0009000000-3a9ffadb8ced05c4f2f1
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, NegativeLC-MS/MSsplash10-006x-0900000000-26410712c1d9fca3970f
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, NegativeLC-MS/MSsplash10-02ml-0900000000-b8d8d8a38eb5ff79811d
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, NegativeLC-MS/MSsplash10-03di-2900000000-417be0cb4c8a324c3ae4
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, NegativeLC-MS/MSsplash10-03di-5900000000-ca80edf051507a622e91
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, PositiveLC-MS/MSsplash10-014i-0009000000-e8f56e6282043759674e
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, PositiveLC-MS/MSsplash10-00vi-0933000000-aaee0f5a149286ba8834
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, PositiveLC-MS/MSsplash10-0059-1900000000-52e4e1bcfef85a6bafea
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, PositiveLC-MS/MSsplash10-0faj-2900000000-e412e77b79750d8bb513
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, PositiveLC-MS/MSsplash10-0uea-4900000000-76d786153c89ecf65f8c
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-00fr-0930000000-01f54848489d6a7b4da4
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-00di-0970000000-49b8e0b710b97f5d5da6
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-00kf-0900000000-cf634d229fba340e6e3b
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-001i-0900000000-09008c251fc8dd33b8bf
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-00e9-4900000000-350ded3a1f334f8103b1
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-052f-0900000000-14196f34248aa3cac7fc
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-0f79-0900000000-0a386c1d346e41534469
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-0udi-0900000000-4296a8171c03e3b2b689
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0900000000-03ff389cfe57bfe1fd9c
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-0609000000-b84b01672e464bc22fd3
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00dl-0900000000-89c78d833473150dbb81
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-02ml-0900000000-5841cf0c06dbaf954888
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-0900000000-16045980b681df0f594e
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-0900000000-d5953e08a3cb69d2aa2b
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-0900000000-a96b0d1efb86be171a6c
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-0509000000-9a6f4001c5a99813717f
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00dl-0900000000-388913e38d155f159d8d
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-02ml-0900000000-ee40ae04c260a3e09d17
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-1900000000-abb56ffad9b8b3657fcd
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-0900000000-fc2323b7a02a32a4979b
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0900000000-417353715450c67cfd73
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-03di-0009000000-3a9ffadb8ced05c4f2f1
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-006x-0900000000-26410712c1d9fca3970f
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-02ml-0900000000-b8d8d8a38eb5ff79811d
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-03di-2900000000-417be0cb4c8a324c3ae4
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-03di-5900000000-ca80edf051507a622e91
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004i-0920000000-fc5b810da0b99c7a47cc
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0059-0900000000-563bf123943826a4ee15
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0059-0900000000-a889fa5e489d1d1c27fc
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004j-0900000000-fd0ea2e984b4ce58b9df
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0009000000-38d3c73e4bffe2808538
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0970000000-8fe41e639371ccd5e039
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0009000000-e04b1b88fd5e019229ed
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-1910000000-c598e7dc2ece622bf853
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-1900000000-cd58b43d9168d2d35586
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0ugj-2900000000-dfaf3c18a40f92e31b5c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0ugj-3900000000-6bf7695693403dfcd90e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0f8a-6900000000-6641dd270863ff1455a6
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0009000000-4e5b09bcb0bf176315fd
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-1910000000-7843ceb16946d25ec84e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-1900000000-e766825d33d37bb6a6ca
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0ugj-2900000000-7bdea76f53e7741a40ea
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0ugj-3900000000-19db1770011ff7821179
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0f8a-5900000000-832e92905bd741949ba1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0970000000-d42ebac033e2666b1a5a
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-014i-0009000000-e8f56e6282043759674e
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00vi-0933000000-6c2174f482eeb1972875
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0059-1900000000-80d184a4a9e276c6febc
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0faj-2900000000-e412e77b79750d8bb513
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0uea-4900000000-8328552b5ee619f35b40
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-00fr-0930000000-3b023ec7d141989d3665
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0fba-1900000000-2ae676ccc8236775fb31
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0ugj-3900000000-839171139828c12c8e0b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0970000000-272c202bff43d84dc736
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0960000000-05f9a8cbabf7dc30eb5d
MS/MS Spectrum - , positiveLC-MS/MSsplash10-01di-0934000000-7c7227a3ac57df988aee
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Amines
Direct Parent
Aralkylamines
Alternative Parents
Heteroaromatic compounds / Furans / Trialkylamines / C-nitro compounds / Sulfenyl compounds / Propargyl-type 1,3-dipolar organic compounds / Oxacyclic compounds / Organic oxoazanium compounds / Dialkylthioethers / Dialkylamines
show 5 more
Substituents
Aralkylamine / Furan / Heteroaromatic compound / C-nitro compound / Tertiary amine / Tertiary aliphatic amine / Organic nitro compound / Secondary aliphatic amine / Organic oxoazanium / Secondary amine
show 16 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
C-nitro compound, tertiary amino compound, furans (CHEBI:8776)

Targets

Details
1. Histamine H2 receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and diff...
Gene Name
HRH2
Uniprot ID
P25021
Uniprot Name
Histamine H2 receptor
Molecular Weight
40097.65 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Pattichis K, Louca LL: Histamine, histamine H2-receptor antagonists, gastric acid secretion and ulcers: an overview. Drug Metabol Drug Interact. 1995;12(1):1-36. [PubMed:7554999]
Details
2. Acetylcholinesterase
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serine hydrolase activity
Specific Function
Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.
Gene Name
ACHE
Uniprot ID
P22303
Uniprot Name
Acetylcholinesterase
Molecular Weight
67795.525 Da
References
  1. Petroianu GA, Arafat K, Schmitt A, Hasan MY: Weak inhibitors protect cholinesterases from strong inhibitors (paraoxon): in vitro effect of ranitidine. J Appl Toxicol. 2005 Jan-Feb;25(1):60-7. [PubMed:15669026]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Petroianu GA, Arafat K, Schmitt A, Hasan MY: Weak inhibitors protect cholinesterases from strong inhibitors (paraoxon): in vitro effect of ranitidine. J Appl Toxicol. 2005 Jan-Feb;25(1):60-7. [PubMed:15669026]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Details
4. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Bednarczyk D, Ekins S, Wikel JH, Wright SH: Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol. 2003 Mar;63(3):489-98. [PubMed:12606755]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Lentz KA, Polli JW, Wring SA, Humphreys JE, Polli JE: Influence of passive permeability on apparent P-glycoprotein kinetics. Pharm Res. 2000 Dec;17(12):1456-60. [PubMed:11303953]
  2. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389]
  3. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019]
  4. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Tahara H, Kusuhara H, Chida M, Fuse E, Sugiyama Y: Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists. J Pharmacol Exp Ther. 2006 Mar;316(3):1187-94. Epub 2005 Nov 16. [PubMed:16291876]
  2. VanWert AL, Gionfriddo MR, Sweet DH: Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology. Biopharm Drug Dispos. 2010 Jan;31(1):1-71. doi: 10.1002/bdd.693. [PubMed:19953504]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Meyer MJ, Seitz T, Brockmoller J, Tzvetkov MV: Effects of genetic polymorphisms on the OCT1 and OCT2-mediated uptake of ranitidine. PLoS One. 2017 Dec 13;12(12):e0189521. doi: 10.1371/journal.pone.0189521. eCollection 2017. [PubMed:29236753]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Curator comments
Inhibitory activity was demonstrated in vitro on human OAT1 expressed on CHO cells, while substrate activity was demonstrated in HEK293 cells.
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. VanWert AL, Gionfriddo MR, Sweet DH: Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology. Biopharm Drug Dispos. 2010 Jan;31(1):1-71. doi: 10.1002/bdd.693. [PubMed:19953504]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:45